(VIANEWS) – Shares of DexCom (NASDAQ: DXCM) jumped 9.01% to $120.75 at 15:59 EST on Thursday, following the last session’s downward trend. NASDAQ is jumping 0.41% to $11,426.59, after four successive sessions in a row of losses. This seems, so far, a somewhat positive trend exchanging session today.
DexCom’s last close was $110.76, 17.81% under its 52-week high of $134.76.
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $5.2.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 23.2. Meaning, the purchaser of the share is investing $23.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.19%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.4%, now sitting on 2.79B for the twelve trailing months.
More news about DexCom (DXCM).
